合併症のない尿路感染症の世界市場レポート 2025年

合併症のない尿路感染症市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.8％で142億7,000万米ドルに成長します。予測期間中に予測される成長は、細菌感染症の増加、人口の高齢化、性行為の増加、尿路感染症の増加、避妊薬の使用の増加に起因しています。この期間の主な動向としては、遠隔医療の開発、遠隔医療ソリューションの主な発展、新薬の創出、尿路感染症治療薬の進歩、研究開発の継続的な進展などが挙げられます。

慢性腎臓病（CKD）の有病率の増加は、合併症のない尿路感染症（UTI）市場の拡大を牽引すると予想されます。CKDは、腎臓が徐々に機能を失い、老廃物や体液が体内に蓄積する長期的な疾患です。CKD患者の増加は、糖尿病の有病率の増加が主な原因です。長期にわたる高血糖は腎臓にダメージを与え、老廃物を適切に濾過する能力を損なうからです。CKDは免疫系を弱めるため、尿路感染症にかかりやすくなります。さらに、腎臓の機能が低下すると尿が滞留しやすくなり、細菌が繁殖しやすい環境となります。例えば、2023年6月、Kidney Research UKは、英国における慢性腎臓病による腎臓移植の増加を報告しており、その数は2021年の2,863件から2023年には2,976件に増加しています。したがって、慢性腎臓病の割合の増加が合併症のない尿路感染症市場の成長を促進すると予想されます。

糖尿病罹患率の上昇が合併症のない尿路感染症市場の成長を促進すると予想されます。糖尿病は、インスリン分泌不足やインスリン利用不足による高血糖を特徴とする慢性代謝疾患です。糖尿病患者の増加は、食生活の乱れや運動不足といった不健康な生活習慣によるところが大きいです。加工食品や糖分の多い製品の消費の増加と座りっぱなしの行動が、2型糖尿病の主要な危険因子である肥満率の上昇を招いています。血糖値の上昇は尿路の細菌増殖を促進し、尿路結石の発生率を高める。さらに、糖尿病は免疫系を低下させ、尿路結石を含む感染症に対抗することをより困難にします。例えば、2024年3月、OHID（Office for Health Improvement &Disparities）は、イングランドにおいて、1型糖尿病患者が必要な8つのケアプロセスをすべて受けた割合は、わずか1年間で35.2％から43.8％に増加したと報告しました。その結果、糖尿病患者の増加が合併症のない尿路感染症市場の成長を促進すると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界合併症のない尿路感染症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の合併症のない尿路感染症市場：成長率分析
• 世界の合併症のない尿路感染症市場の実績：規模と成長, 2019-2024
• 世界の合併症のない尿路感染症市場の予測：規模と成長, 2024-2029, 2034F
• 世界合併症のない尿路感染症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の合併症のない尿路感染症市場テストの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 尿検査
• 尿培養検査
• 感受性試験
• 世界の合併症のない尿路感染症市場薬物による、実績と予測, 2019-2024, 2024-2029F, 2034F
• ペニシリンとその組み合わせ
• キノロン
• セファロスポリン
• アゾールとアムホテリシンB
• ニトロフラン
• その他の薬物
• 世界の合併症のない尿路感染症市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 診断ラボ
• 調査機関
• 世界の合併症のない尿路感染症市場尿検査の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ディップスティックテスト
• 顕微鏡検査
• 自動尿検査
• 世界の合併症のない尿路感染症市場尿培養の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 寒天培地培養
• ブロス培養
• 発色培地
• 世界の合併症のない尿路感染症市場感受性試験の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ディスク拡散法
• 自動感受性試験
• 分子感受性試験

第7章 地域別・国別分析

• 世界の合併症のない尿路感染症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の合併症のない尿路感染症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 合併症のない尿路感染症市場：競合情勢
• 合併症のない尿路感染症市場：企業プロファイル
  • Cardinal Health Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • GSK plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Eli Lilly and Company
• Siemens AG
• Strykar Healthcare
• John Hopkins Medicine
• Shionogi & Co. Ltd.
• Sysmex Corporation
• Bio-Rad Laboratories Inc
• Cipla Inc.
• UTILITY therapeutics Ltd
• Orchid Pharma Limited
• ACON Labs
• Sonika Lifesciences
• Emergency Care BC
• EB Medicine
• Iterum Therapeutics PLC

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 合併症のない尿路感染症市場2029：新たな機会を提供する国
• 合併症のない尿路感染症市場2029：新たな機会を提供するセグメント
• 合併症のない尿路感染症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

An uncomplicated urinary tract infection (UTI) is a bacterial infection of the bladder or urethra that typically occurs in healthy individuals without any structural issues or underlying health conditions. It most commonly affects the bladder (cystitis) and is caused by common uropathogens, such as Escherichia coli (E. coli). The primary goals of diagnosis and treatment are to relieve symptoms, prevent complications, and eradicate the infection using short-course antibiotics, ensuring a quick recovery without long-term effects.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main diagnostic tests in the uncomplicated urinary tract infection market include urinalysis, urine cultures, and susceptibility testing. Urinalysis is a laboratory test that analyzes a urine sample to detect and measure various substances, such as proteins, glucose, red and white blood cells, and bacteria. The market also includes a range of drugs, such as penicillin and its combinations, quinolones, cephalosporins, azoles and amphotericin B, nitrofurans, and others, along with various end-users such as hospitals, diagnostic labs, and research institutes.

The uncomplicated urinary tract infection market research report is one of a series of new reports from The Business Research Company that provides uncomplicated urinary tract infection market statistics, including uncomplicated urinary tract infection industry global market size, regional shares, competitors with an uncomplicated urinary tract infection market share, detailed uncomplicated urinary tract infection market segments, market trends and opportunities, and any further data you may need to thrive in the uncomplicated urinary tract infection industry. This uncomplicated urinary tract infection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The uncomplicated urinary tract infection market size has grown strongly in recent years. It will grow from $10.24 billion in 2024 to $10.98 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth observed during the historic period can be attributed to the increasing cases of renal failure, rising instances of bladder cancer, a higher prevalence of chronic kidney diseases, a growing use of urinary catheters, and the rising prevalence of diabetes.

The uncomplicated urinary tract infection market size is expected to see strong growth in the next few years. It will grow to $14.27 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth projected during the forecast period can be attributed to the rise in bacterial infections, an aging population, increased sexual activity, a growing number of urinary tract infections, and the rising use of contraceptives. Key trends during this period include the development of telemedicine, advancements in telehealth solutions, the creation of novel drugs, progress in urinary tract infection therapeutics, and continued advancements in research and development.

The growing prevalence of chronic kidney diseases (CKD) is expected to drive the expansion of the uncomplicated urinary tract infection (UTI) market. CKD is a long-term condition where the kidneys gradually lose their function, causing waste and fluid to build up in the body. The rise in CKD cases is largely attributed to the increasing prevalence of diabetes, as high blood sugar over time can damage the kidneys, impairing their ability to filter waste properly. CKD weakens the immune system, making individuals more vulnerable to urinary tract infections. Furthermore, poor kidney function can lead to urine retention, creating an environment conducive to bacterial growth. For example, in June 2023, Kidney Research UK reported an increase in kidney transplants in the UK due to chronic kidney disease, with the number rising from 2,863 transplants in 2021 to 2,976 in 2023. Therefore, the increasing rates of chronic kidney diseases are expected to fuel the growth of the uncomplicated urinary tract infection market.

The rising incidence of diabetes is expected to drive the growth of the uncomplicated urinary tract infection market. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels due to insufficient insulin production or poor insulin utilization. The rise in diabetes cases is largely due to unhealthy lifestyle habits, such as poor diet and lack of physical activity. The increased consumption of processed foods and sugary products, along with sedentary behavior, has contributed to higher obesity rates, a major risk factor for type 2 diabetes. Elevated blood sugar levels foster bacterial growth in the urinary tract, leading to a higher incidence of UTIs. Moreover, diabetes can compromise the immune system, making it more difficult for the body to combat infections, including UTIs. For instance, in March 2024, the Office for Health Improvement & Disparities (OHID) reported that in England, the percentage of individuals with Type 1 diabetes receiving all eight required care processes increased from 35.2% to 43.8% in just one year. Consequently, the rising cases of diabetes are expected to drive the growth of the uncomplicated urinary tract infection market.

Key companies in the uncomplicated urinary tract infection (UTI) market are focusing on developing new antibiotics to improve treatment effectiveness and address the challenge of antibiotic-resistant bacteria. Antibiotics work by killing or inhibiting the growth of bacteria in the body to treat infections. For example, in April 2024, the U.S. Food and Drug Administration (FDA) approved Pivya (pivmecillinam) tablets for the treatment of uncomplicated urinary tract infections in adult females. This tablet targets UTIs caused by susceptible strains of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus. Pivmecillinam is a prodrug that converts into mecillinam, a beta-lactam antibiotic that works by disrupting the cell wall synthesis of gram-negative bacteria. These advancements in antibiotic development are strengthening the effectiveness of UTI treatments.

Major players in the uncomplicated urinary tract infection market are Cardinal Health, Pfizer Inc., Bayer AG, AstraZeneca plc, GSK plc, Eli Lilly and Company, Siemens AG, Strykar Healthcare, John Hopkins Medicine, Shionogi & Co. Ltd., Sysmex Corporation, Bio-Rad Laboratories Inc, Cipla Inc., UTILITY therapeutics Ltd, Orchid Pharma Limited, ACON Labs, Sonika Lifesciences, Emergency Care BC, EB Medicine, Iterum Therapeutics PLC.

North America was the largest region in the uncomplicated urinary tract infection market in 2024. The regions covered in uncomplicated urinary tract infection report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the uncomplicated urinary tract infection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The uncomplicated urinary tract infection market consists of sales of urinary analgesics, pH-altering agents, and hydration and supportive supplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Uncomplicated Urinary Tract Infection Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on uncomplicated urinary tract infection market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for uncomplicated urinary tract infection ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The uncomplicated urinary tract infection market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Test Type: Urinalysis; Urine Cultures; Susceptibility Testing
• 2) By Drug: Penicillin And Combinations; Quinolones; Cephalosporin; Azoles And Amphotericin B; Nitrofurans; Other Drugs
• 3) By End-Users: Hospitals; Diagnostic Labs; Research Institutes
• Subsegments:
• 1) By Urinalysis: Dipstick Tests; Microscopic Examination; Automated Urinalysis
• 2) By Urine Cultures: Agar Plate Culture; Broth Culture; Chromogenic Media
• 3) By Susceptibility Testing: Disk Diffusion Method; Automated Susceptibility Testing; Molecular Susceptibility Testing
• Companies Mentioned: Cardinal Health; Pfizer Inc.; Bayer AG; AstraZeneca plc; GSK plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Uncomplicated Urinary Tract Infection Market Characteristics

3. Uncomplicated Urinary Tract Infection Market Trends And Strategies

4. Uncomplicated Urinary Tract Infection Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Uncomplicated Urinary Tract Infection Growth Analysis And Strategic Analysis Framework

• 5.1. Global Uncomplicated Urinary Tract Infection PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Uncomplicated Urinary Tract Infection Market Growth Rate Analysis
• 5.4. Global Uncomplicated Urinary Tract Infection Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Uncomplicated Urinary Tract Infection Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Uncomplicated Urinary Tract Infection Total Addressable Market (TAM)

6. Uncomplicated Urinary Tract Infection Market Segmentation

• 6.1. Global Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Urinalysis
• Urine Cultures
• Susceptibility Testing
• 6.2. Global Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Penicillin And Combinations
• Quinolones
• Cephalosporin
• Azoles And Amphotericin B
• Nitrofurans
• Other Drugs
• 6.3. Global Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Diagnostic Labs
• Research Institutes
• 6.4. Global Uncomplicated Urinary Tract Infection Market, Sub-Segmentation Of Urinalysis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dipstick Tests
• Microscopic Examination
• Automated Urinalysis
• 6.5. Global Uncomplicated Urinary Tract Infection Market, Sub-Segmentation Of Urine Cultures, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Agar Plate Culture
• Broth Culture
• Chromogenic Media
• 6.6. Global Uncomplicated Urinary Tract Infection Market, Sub-Segmentation Of Susceptibility Testing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Disk Diffusion Method
• Automated Susceptibility Testing
• Molecular Susceptibility Testing

7. Uncomplicated Urinary Tract Infection Market Regional And Country Analysis

• 7.1. Global Uncomplicated Urinary Tract Infection Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Uncomplicated Urinary Tract Infection Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Uncomplicated Urinary Tract Infection Market

• 8.1. Asia-Pacific Uncomplicated Urinary Tract Infection Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Uncomplicated Urinary Tract Infection Market

• 9.1. China Uncomplicated Urinary Tract Infection Market Overview
• 9.2. China Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Uncomplicated Urinary Tract Infection Market

• 10.1. India Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Uncomplicated Urinary Tract Infection Market

• 11.1. Japan Uncomplicated Urinary Tract Infection Market Overview
• 11.2. Japan Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Uncomplicated Urinary Tract Infection Market

• 12.1. Australia Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Uncomplicated Urinary Tract Infection Market

• 13.1. Indonesia Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Uncomplicated Urinary Tract Infection Market

• 14.1. South Korea Uncomplicated Urinary Tract Infection Market Overview
• 14.2. South Korea Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Uncomplicated Urinary Tract Infection Market

• 15.1. Western Europe Uncomplicated Urinary Tract Infection Market Overview
• 15.2. Western Europe Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Uncomplicated Urinary Tract Infection Market

• 16.1. UK Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Uncomplicated Urinary Tract Infection Market

• 17.1. Germany Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Uncomplicated Urinary Tract Infection Market

• 18.1. France Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Uncomplicated Urinary Tract Infection Market

• 19.1. Italy Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Uncomplicated Urinary Tract Infection Market

• 20.1. Spain Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Uncomplicated Urinary Tract Infection Market

• 21.1. Eastern Europe Uncomplicated Urinary Tract Infection Market Overview
• 21.2. Eastern Europe Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Uncomplicated Urinary Tract Infection Market

• 22.1. Russia Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Uncomplicated Urinary Tract Infection Market

• 23.1. North America Uncomplicated Urinary Tract Infection Market Overview
• 23.2. North America Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Uncomplicated Urinary Tract Infection Market

• 24.1. USA Uncomplicated Urinary Tract Infection Market Overview
• 24.2. USA Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Uncomplicated Urinary Tract Infection Market

• 25.1. Canada Uncomplicated Urinary Tract Infection Market Overview
• 25.2. Canada Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Uncomplicated Urinary Tract Infection Market

• 26.1. South America Uncomplicated Urinary Tract Infection Market Overview
• 26.2. South America Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Uncomplicated Urinary Tract Infection Market

• 27.1. Brazil Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Uncomplicated Urinary Tract Infection Market

• 28.1. Middle East Uncomplicated Urinary Tract Infection Market Overview
• 28.2. Middle East Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Uncomplicated Urinary Tract Infection Market

• 29.1. Africa Uncomplicated Urinary Tract Infection Market Overview
• 29.2. Africa Uncomplicated Urinary Tract Infection Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Uncomplicated Urinary Tract Infection Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Uncomplicated Urinary Tract Infection Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Uncomplicated Urinary Tract Infection Market Competitive Landscape And Company Profiles

• 30.1. Uncomplicated Urinary Tract Infection Market Competitive Landscape
• 30.2. Uncomplicated Urinary Tract Infection Market Company Profiles
  • 30.2.1. Cardinal Health Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GSK plc Overview, Products and Services, Strategy and Financial Analysis

31. Uncomplicated Urinary Tract Infection Market Other Major And Innovative Companies

• 31.1. Eli Lilly and Company
• 31.2. Siemens AG
• 31.3. Strykar Healthcare
• 31.4. John Hopkins Medicine
• 31.5. Shionogi & Co. Ltd.
• 31.6. Sysmex Corporation
• 31.7. Bio-Rad Laboratories Inc
• 31.8. Cipla Inc.
• 31.9. UTILITY therapeutics Ltd
• 31.10. Orchid Pharma Limited
• 31.11. ACON Labs
• 31.12. Sonika Lifesciences
• 31.13. Emergency Care BC
• 31.14. EB Medicine
• 31.15. Iterum Therapeutics PLC

32. Global Uncomplicated Urinary Tract Infection Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Uncomplicated Urinary Tract Infection Market

34. Recent Developments In The Uncomplicated Urinary Tract Infection Market

35. Uncomplicated Urinary Tract Infection Market High Potential Countries, Segments and Strategies

• 35.1 Uncomplicated Urinary Tract Infection Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Uncomplicated Urinary Tract Infection Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Uncomplicated Urinary Tract Infection Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r35002_Uncomplicated_Urinary_Tract_Infection_GMR_2025